Kayla Howard

Dr. Kayla Howard

Experimental Medicine, Stellenbosch University, Cape Town, Western Cape, South Africa
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSSithole Navela Sithole
Sithole Navela Sithole
CPCarla Monique Pieterse
Carla Monique Pieterse
KHKayla Howard
Kayla Howard
Abe KasongaAbe Kasonga
Abe Kasonga
Osteoclasts are large, multinucleated cells that are responsible for the resorption of bone. Bone degenerative diseases, such as osteoporosis, are characterized by overactive osteoclasts. Receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) binding to its receptor on osteoclast precursors will trigger osteoclast formation and resorption. The production of reactive oxygen species (ROS) is known to play a crucial role in RANKL-induced osteoclast formation and resorption. G-protein coupled receptor 120 (GPR120) signalling has been shown to affect osteoclast formation, but the exact mechanisms of action require further investigation. RAW264.7 murine macrophages were seeded into culture plates and exposed to the GPR120 agonist, TUG-891, at varying concentrations (20–100 µM) and RANKL to induce osteoclast formation. TUG-891 was shown to inhibit osteoclast formation and resorption without affecting cell viability in RAW264.7 macrophages. TUG-891 further decreased ROS production when compared to RANKL only cells. Antioxidant proteins, Nrf2, HO-1 and NQO1 were shown to be upregulated while the ROS inducing protein, Nox1, was downregulated by TUG-891. Gene silencing revealed that TUG-891 exerted its effects specifically through GPR120. This study reveals that GPR120 signalling may inhibit osteoclast formation and resorption through inhibition on ROS production.

11 March 2025 in International Wound Journal
Verified
Journal Article
Open access
PIPatricia Joan Idensohn
Patricia Joan Idensohn
KGKeenen Gilbert
Keenen Gilbert
KBKiara Boodhoo
Kiara Boodhoo
KHKayla Howard
Kayla Howard
MVMari van de Vyver
Mari van de Vyver
The incidence of hard‐to‐heal wounds is rising globally with adverse effects on quality of life. Yet, there is no reliable data available on hard‐to‐heal wound prevalence, aetiology, and outcomes in a low‐to‐middle income country without improper care being a confounding factor. In this retrospective study of 460 individuals (876 wounds) that received appropriate standard of care at a specialised wound care clinic in the Kwazulu‐Natal province of South Africa, acute/traumatic wounds were most prevalent (230/460, 50%) followed by ulcers (173/460, 38%) (DFUs 13%, VLUs 12%, PIs 11%, MLUs < 1%, ALUs < 1%) and atypical wounds (55/460, 12%) (atypical wounds 8%, vectors 4%). Definitions for wound aetiologies are provided. Delayed referral for specialised wound care was evident for individuals with ulcers. 103/460 (22%) individuals did not respond to the standard of care and were classified as hard‐to‐heal (< 40% wound closure after 4 weeks and/or > 12 weeks of the standard of care). Diabetes mellitus (45/103, 44%) and wound infection (44/103, 43%) accounted for poor healing trajectories in the hard‐to‐heal cohort, whereas 14/103 (13%) individuals had other comorbidities. High prevalence rates of hard‐to‐heal wounds in the heterogenous South African population necessitate recognition of wound management as a specialty in South Africa.

29 March 2026 in Wound Repair and Regeneration
Verified
Journal Article
Open access
PDF file
KHKayla Howard
Kayla Howard
PDPriyanka Dhanraj
Priyanka Dhanraj
KAKayleigh Armstrong
Kayleigh Armstrong
MVMari van de Vyver
Mari van de Vyver
Topically applied autologous blood clot therapy (TABCT) is a low‐cost regenerative modality proposed for complex wounds, yet its biological mechanism of action remains poorly defined. We investigated whether factors released from autologous blood clots promote peripheral blood mononuclear cell (PBMC) chemotaxis and fibroblast migration, and whether these effects are altered in individuals with metabolic syndrome/type 2 diabetes (MetS/DM). Twenty‐two participants (controls n = 12; MetS/DM n = 10) were recruited. Autologous clots were generated ex vivo, cultured for 24 h, and the secretome analysed for total protein, PDGF‐BB, P‐selectin and CCL‐5. PBMC basal activation (ROS production, phagocytosis, migration, Ca 2+ flux) was assessed, followed by live‐cell chemotaxis assays. Human dermal fibroblast migration was evaluated using a scratch assay. MetS/DM‐derived PBMCs demonstrated heightened basal activation, including increased ROS production, migration velocity and sustained intracellular Ca 2+ flux. Clots from MetS/DM participants released less total protein but significantly higher P‐selectin levels, consistent with platelet hyperactivation. Despite containing measurable growth factors, clot‐derived secretomes did not significantly enhance PBMC migration velocity or distance travelled, although directionality modestly increased. Similarly, secretome exposure failed to stimulate fibroblast‐mediated wound closure (< 30% closure across groups). Pretreatment of blood with metformin, prednisone or amoxicillin had negligible effects on secretome composition or functional outcomes. These findings demonstrate that while TABCT‐derived secretomes exhibit chemotactic properties, they do not substantially promote immune cell recruitment or fibroblast migration in vitro. The clinical benefits of TABCT may therefore be attributable primarily to its fibrin scaffold properties rather than bioactive factor release. Further mechanistic and translational studies are warranted.